Ads
related to: meningococcal encephalitis vaccine cost
Search results
Results From The WOW.Com Content Network
Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. [9] Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. [ 9 ] [ 10 ] The vaccines are between 85 and 100% effective for at least two years. [ 9 ]
NmVac4-A/C/Y/W-135 is the commercial name for a polysaccharide vaccine that protects against meningococcal meningitis caused by Neisseria meningitidis, specifically the serotypes A, C, Y, and W-135. This vaccine is part of a broader group of meningococcal vaccines.
Penbraya is a pentavalent conjugate vaccine developed by Pfizer for the prevention of invasive meningococcal disease in people 10 through 25 years of age. [4] Invasive meningococcal disease, caused by the bacterium Neisseria meningitidis, can lead to serious conditions such as meningitis (inflammation of the brain and spinal cord lining) and sepsis. [5]
Penbraya combines components from those two vaccines and is approved for use in individuals 10 through 25 years of age. It is administered as a two-dose series given six months apart.
1.6 J07AH Meningococcal vaccines. 1.7 J07AJ Pertussis vaccines. ... J07BA Encephalitis vaccines. J07BA01 Encephalitis, tick-borne, inactivated, whole virus
The first vaccine to prevent meningococcal serogroup B (meningitis B) disease was approved by the European Commission on 22 January 2013. [12] Vaccines offer significant protection from three to five years (plain polysaccharide vaccine Menomune, Mencevax and NmVac-4) to more than eight years (conjugate vaccine Menactra). [13] [14]
For premium support please call: 800-290-4726 more ways to reach us
A meningococcal polysaccharide vaccine (MPSV4) has been available since the 1970s and is the only meningococcal vaccine licensed for people older than 55. MPSV4 may be used in people 2–55 years old if the MCV4 vaccines are not available or contraindicated. Two meningococcal conjugate vaccines (MCV4) are licensed for use in the U.S. The first ...